15 Jan
2020
16:30 E.S.T.

First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia

Read more

12 Jan
2020
16:00 E.S.T.

Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement

Read more

06 Jan
2020
16:30 E.S.T.

An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery

Read more

02 Dec
2019
16:30 E.S.T.

1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Read more

20 Nov
2019
16:30 E.S.T.

Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells

Read more

13 Nov
2019
16:30 E.S.T.

Cellectis Publishes Creation of “Smart CAR T-Cells” for Potentially Safer, More Effective Treatments for Cancer in Nature Communications

Read more

06 Nov
2019
16:47 E.S.T.

Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019

Read more

31 Oct
2019
16:30 E.S.T.

Cellectis to Hold Third Quarter and First Nine Months 2019 Earnings Call on Thursday, November 7, 2019 at 8:00 AM EST

Read more

30 Oct
2019
16:30 E.S.T.

The Institut Pasteur and Cellectis extend exclusive license rights by granting genOway the authority to take action against infringement

Read more

29 Oct
2019
16:30 E.S.T.

First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma

Read more